Targeting ADAM17 inhibits human colorectal adenocarcinoma progression and tumor-initiating cell frequency.
Dosch J, Ziemke E, Wan S, Luker K, Welling T, Hardiman K, Fearon E, Thomas S, Flynn M, Rios-Doria J, Hollingsworth R, Herbst R, Hurt E, Sebolt-Leopold J.
Dosch J, et al.
Oncotarget. 2017 May 10;8(39):65090-65099. doi: 10.18632/oncotarget.17780. eCollection 2017 Sep 12.
Oncotarget. 2017.
PMID: 29029414
Free PMC article.